Search
cobimetinib
Indications:
- metastatic melanoma
- *BRAF V600E or BRAF V600K gene mutation-positive
- craniopharyngioma [2]
- for use in combination with vemurafenib [1]
Mechanism of action:
- inhibits MEK
Notes:
- investigational; not yet FDA-approved
- development by Roche/Exelixis [1]
General
small inhibitory antineoplastic agent (ib drug)
enzyme inhibitor
References
- Mescape Oncology. Sept 30, 2014
New Standard in Melanoma: Combo of BRAF and MEK Inhibitors.
http://www.medscape.com/viewarticle/832566?nlid=66983_2202
- ClinicalTrials.gov
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation
Positive Craniopharyngioma.
https://clinicaltrials.gov/study/NCT03224767